Navigation Links
EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia Models
Date:12/10/2007

Prolonged Survival in Leukemia Models Demonstrated

ROCKVILLE, Md., Dec. 10 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of preclinical results in preclinical leukemia models for its antimitotic agent, ENMD-1198, in combination with vincristine. The data were presented by EntreMed collaborator, Dr. Maria Kavallaris, at the American Society of Hematology Annual Meeting being held December 8-11, 2007 in Atlanta, Georgia.

(Photo: Newscom: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO)

Data presented demonstrate that ENMD-1198, administered as a single agent, is effective in significantly delaying the growth of leukemia xenografts in vivo. Combination studies with ENMD-1198 and another microtubule targeting agent commonly used in the treatment of leukemias, vincristine, demonstrate synergistic effects on leukemia cells in vitro and tolerability of doses that prolonged survival in leukemia xenograft models.

ENMD-1198, a new chemical entity (NCE) derived from 2-methoxyestradiol (2ME2), was designed to decrease metabolism while retaining 2ME2's multiple mechanisms of action, including inducing apoptosis, disrupting microtubules, and inhibiting HIF-1alpha. In prior preclinical studies, ENMD-1198, an orally active antimitotic agent, leads to arrest of cell division and apoptosis in tumor cells. ENMD-1198 also exerts antiangiogenic activity that further contributes to its overall antitumor effects.

Mark R. Bray, Ph.D., EntreMed Vice President, Research, commented on the results, "We continue to be encouraged by the potent preclinical antitumor activity of ENMD-1198 as a single agent and in combination with other chemotherapeutics. The observation that two active microtubule agents can be combined to produce synergistic activity at tolerated doses is quite encouraging. ENMD-1198 is currently being evaluated in a Phase 1 study in refractory solid tumor patients and we anticipate commencement of Phase 2 clinical studies in 2008."

To view the poster presentation, visit the Company's web site at http://www.entremed.com.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R) NCD (2-methoxyestradiol or 2ME2) is currently in multiple Phase 2 clinical trials for cancer. MKC-1, an oral cell-cycle regulator, is in multiple Phase 1 and 2 studies for cancer. ENMD-1198, a novel tubulin-binding agent, is in Phase 1 studies in advanced cancers. Panzem(R) is also in preclinical development for rheumatoid arthritis, and ENMD-2076, a dual-acting Aurora-angiogenesis inhibitor, is in preclinical development for cancer. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

CONTACT:

Ginny Dunn

Associate Director, Corporate Communications & Investor Relations

EntreMed, Inc.

240.864.2643


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. EntreMed Receives Deloitte Technology Fast 50 Award
2. EntreMed to Present at the Bio 2007 Investor Forum
3. EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study
4. EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference
5. EntreMed Reports Third Quarter 2007 Financial Results
6. Updated GOLD report presents new understandings in diagnosis, treatment and prevention of COPD
7. The Art Of Maternity(TM) at Destination Maternity(R) Presents A Sacred Passage Into Motherhood; the Art of Belly Masking to Belly Casting
8. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
9. VNUS Medical Technologies Presents at William Blair Small-Cap Growth Stock Conference
10. NARSAD - Worlds Leading Mental Health Research Charity - Presents 19th Annual New York Mental Health Symposium, Oct. 19th & 20th
11. Retirement Living TV Presents Sex, Drugs and Rock N Roll
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... LaserShip, a regional parcel carrier that services ... of Eastern Michigan last Friday in order to aid in the Flint water crisis. ... include a facility located in Clio, only 15 miles away from Flint. , “We ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... (VRI) within Healthcare, recently partnered with Heart City Health Center to ... nearly 23 years, Heart City Health Center has provided the Elkhart community with ...
(Date:2/10/2016)... ... 2016 , ... 10 Best Water is excited to announce a ... owners that topped the list as a result of their commitment to offering clients ... was Tibet 5100, a top notch water company that specializes in providing the public ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... organization, welcomes S.S. Nesbitt as the latest addition to its growing list of ... other locations throughout the Southeast, from Orlando to Huntsville and in between. , ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists are challenged ... Research shows that the Goal Attainment Scale (GAS) captures 20% more change in ... learn more about the Goal Attainment Scale, Education Resources Inc. is offering a ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)...  Fotona, based in the U.S. and Europe ... PRO Lightwalker dental laser at the upcoming 151 st ... 2016 in booth #4815. The ST PRO is a full ... the features of the award winning, industry leading Lightwalker ATS. At ... will be very attractive to many dentists hesitating to incorporate ...
(Date:2/10/2016)... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ... fourth quarter and full year ended December 31, 2015. ... was a transformational year for Vanda with the continued ... market approval of HETLIOZ for Non-24," said Mihael H. ... Fanapt to our U.S. product portfolio builds on this ...
(Date:2/10/2016)... A new report from business intelligence provider GBI Research ... Alzheimer,s disease market will more than double from just under $5 billion in ... Rate (CAGR) of 11%. Canada , France ... Spain , the UK, and Japan , and ... --> Canada , France , ...
Breaking Medicine Technology: